Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eosinophil

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    175 result(s) found for: Eosinophil. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2016-002014-52 Sponsor Protocol Number: FOOTSTEP Start Date*: 2019-01-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB
    Medical condition: severe eosinophilic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022510-11 Sponsor Protocol Number: MEA114092 Start Date*: 2011-02-23
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with ele...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001833-26 Sponsor Protocol Number: OC000459/019/15 Start Date*: 2015-07-21
    Sponsor Name:Atopix Therapeutics Ltd.,
    Full Title: THE EFFECT OF OC000459 ON EOSINOPHILIC AIRWAY INFLAMMATION AND ASTHMA CONTROL IN SUBJECTS WITH REFRACTORY EOSINOPHILIC ASTHMA: A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015470 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006074-10 Sponsor Protocol Number: MEE103219 Start Date*: 2006-06-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/k...
    Medical condition: Eosinophilic oesophagitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004381-33 Sponsor Protocol Number: CQAW039A2127 Start Date*: 2019-12-11
    Sponsor Name:Novartis Pharma AG
    Full Title: Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003117-35 Sponsor Protocol Number: EFC16723 Start Date*: 2021-03-17
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP)
    Medical condition: Chronic rhinosinusitis without nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) SE (Completed) HU (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000082-16 Sponsor Protocol Number: ACESO Start Date*: 2021-01-21
    Sponsor Name:EsoCap AG
    Full Title: A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis
    Medical condition: Active eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004336-16 Sponsor Protocol Number: CC-93538-EE-001 Start Date*: 2021-09-29
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject...
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing) PT (Ongoing) BE (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018249-78 Sponsor Protocol Number: 09115 Start Date*: 2010-05-14
    Sponsor Name:University of Nottingham
    Full Title: Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma
    Medical condition: Refractory Asthma
    Disease: Version SOC Term Classification Code Term Level
    12. 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004401-79 Sponsor Protocol Number: 00000000 Start Date*: 2020-04-15
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: The use of Benralizumab, an interleukin-5 receptor-α monoclonal antibody as treatment of acute exacerbations of airways disease
    Medical condition: Asthma and COPD exacerbations.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010953 COPD exacerbation LLT
    21.1 100000004855 10015575 Exacerbation of asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004391-19 Sponsor Protocol Number: AK002-14 Start Date*: 2020-07-30
    Sponsor Name:Allakos Inc.
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis
    Medical condition: Active Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003078-24 Sponsor Protocol Number: R668-EE-1877 Start Date*: 2020-09-01
    Sponsor Name:Regeneron Pharmaceuticals
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
    Medical condition: Eosinophilic Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2022-001294-31 Sponsor Protocol Number: D5244C00001 Start Date*: 2022-12-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)
    Medical condition: Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eo...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Ongoing) SK (Ongoing) ES (Ongoing) CZ (Ongoing) DK (Ongoing) GR (Ongoing) FI (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004267-32 Sponsor Protocol Number: CQAW039E12201 Start Date*: 2019-04-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia
    Medical condition: Chronic obstructive pulmonary disease with eosinophilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000844-25 Sponsor Protocol Number: R668-EE-1774 Start Date*: 2019-10-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE)
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2018-003242-16 Sponsor Protocol Number: MRx-4DP0004-I-001 Start Date*: 2019-04-09
    Sponsor Name:4D pharma plc
    Full Title: A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004, (a lyophilised formulation of Bif...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003014-12 Sponsor Protocol Number: COPERNICOS_JUJCPR Start Date*: 2021-03-19
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD - Eosinophil-guided Reduction of Inhaled COrticoSteroids (COPERnICOS)
    Medical condition: Clinicaltrial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic azithromycin therapy in patients with severe or very severe chronic obst...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023342-67 Sponsor Protocol Number: C38072/3081 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004579-11 Sponsor Protocol Number: D3251C00004 Start Date*: 2014-07-11
    Sponsor Name:AstraZeneca
    Full Title: A randomised, double-blind, double dummy, 56 week placebo-controlled, multicentre, parallel group, phase 3 study evaluating efficacy and safety of 3 benralizumab doses in patients with moderate to ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed) PL (Completed) BG (Completed) FR (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003013-34 Sponsor Protocol Number: UOL0730 Start Date*: 2020-03-02
    Sponsor Name:University of Leicester
    Full Title: Beyond Allergic Th2 Severe Asthma
    Medical condition: T2-High and T2-Low severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10005503 Blood eosinophils LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 100000004865 10049868 Asthma exacerbation prophylaxis LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA